Revolution Medicines develops pancreatic-cancer drugs targeting RAS mutations.
Revolution Medicines, Inc. (RVMD) is expected to report earnings on Wednesday, November 4, 2026, after the close. Estimated release time 16:05 ET. Consensus EPS estimate is $-2.35.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-05 | Jun 2026 qtr | $-2.04 | $-3.06 | — | $0 |
| 2025-05-07 | Mar 2025 qtr | $-1.12 | $-1.13 | -0.9% | $0 |
| 2024-02-26 | Dec 2023 qtr | $-0.86 | $-1.14 | — | $742.00K |
| 2023-08-08 | Jun 2023 qtr | $-0.83 | $-0.92 | -10.8% | $3.82M |
| 2023-05-08 | Mar 2023 qtr | $-0.84 | $-0.62 | — | $7.01M |
| 2023-02-27 | Dec 2022 qtr | $-0.84 | $-0.63 | — | $15.33M |
| 2022-11-07 | Sep 2022 qtr | $-0.87 | $-0.87 | +0.0% | $3.36M |
| 2022-08-09 | Jun 2022 qtr | $-0.87 | $-0.81 | +6.9% | $9.12M |
RVMD has beaten consensus EPS in 2 of its last 4 scored quarters.
See RVMD on the live calendar →